X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The novel hypoimmune iPSC line is a targeted deletion of the B2M gene, designed to reduce the immunogenicity of product candidates derived from the lines by inhibiting rejection by CD8+ T cells.
Lead Product(s): IPSC-derived Cell Ttransplant Therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Lineage Cell Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
The acquisition includes global immuno-oncology platform of Exacis and its entire pipeline of engineered cell therapy programs for hematologic and solid tumors. Eterna will produce an unlimited number of mRNA-engineered NK and T-cell therapies derived from iPSCs.
Lead Product(s): iPSC-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Recipient: Exacis Biotherapeutics
Deal Size: $49.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition May 02, 2023
Details:
The proceeds will be used to support the development of next-generation mRNA-based therapeutic products and deploying its extensive portfolio of in-licensed mRNA cell engineering patents through strategic partnerships.
Lead Product(s): mRNA-based Therapy
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Lincoln Park Capital
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Agreement April 11, 2023
Details:
Under the agreement, Eterna will develop the novel induced hypoimmune pluripotent stem cell (iPSC) lines, which Lineage will evaluate for development into cell transplant therapies and for the treatment of certain CNS disorders and other neurology indications.
Lead Product(s): Hypoimmune Pluripotent Stem Cell
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Lineage Cell Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 22, 2023
Details:
Under the agreement, Dr. Andreeff will evaluate the capacity of Eterna’s gene-edited induced pluripotent stem (iPS) cell therapeutic candidates to stimulate enhanced immune responses, including their effects on various aspects of T-cell mediated immunity.
Lead Product(s): iPSC-based Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 01, 2022
Details:
The opportunity to partner with Exacis and add next-generation mRNA-based NK (ExaNK) and T cell therapies to oncology portfolio is an important step in advancing Eterna’s mission to realize the potential of cell engineering to provide patients with new medicines.
Lead Product(s): ExaNK
Therapeutic Area: Oncology Product Name: ExaNK
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Exacis Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 17, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
